['chronic kidney disease', 'type 2 diabetes']
['asp8232', 'placebo']

        Inclusion Criteria:

          -  Subject must have an estimated glomerular filtration rate (eGFR) ) >=25 and <75
             ml/min/1.73m2.

          -  Subject must have a documented diagnosis of T2DM and received anti-diabetic medication
             (oral and/or parenteral) for at least 1 year prior to screening

          -  Subject's glycated hemoglobin (HbA1c) level is < 11.0% (<97 mmol/mol) at screening.

          -  Subject is on a stable therapy with an angiotensin-converting-enzyme (ACE) inhibitor
             or angiotensin receptor blockers (ARB) for at least 3 months prior to screening.

          -  Subject who receives anti-hypertensive treatment, non-insulin anti-diabetic agents
             and/or vitamin D receptor activators at screening needs to be on stable therapy for at
             least 3 months prior to screening. Subjects on insulin therapy may have the insulin
             type/dose/schedule adjusted even during the 3 months prior to screening.

          -  If the subject has been subjected to specific dietary interventions then this has to
             be stable over the past 3 months prior to screening visit.

          -  Subject's UACR is ≥ 200 and ≤ 3000 mg/g in a first morning void (FMV) sample at
             screening AND the geometric mean UACR of all FMV samples at visit 4 and at visit 5 is
             ≥ 200 and ≤ 3000 mg/g AND the UACR in at least 3 FMV samples at visit 4 and visit 5 is
             ≥ 200 mg/g.

        Exclusion Criteria:

          -  Subject is on, or previously received, renal replacement therapy (e.g. dialysis or
             kidney transplantation).

          -  Subject has obstructive uropathy or other causes of renal impairment not related to
             parenchymal renal disorder and/or disease of the kidney; or subject currently has or
             has had in the past renal disease secondary to malignancy.

          -  Subject's renal impairment and/or albuminuria is considered to be of other origin than
             Diabetic Kidney Disease.

          -  Subject has known (auto-) immune disorder and/or received immunosuppression for more
             than 2 weeks, cumulatively, within 12 weeks prior to screening or anticipated need for
             immuno-suppressive therapy during the study.

          -  Subject has active urinary tract infection which requires treatment or clinically
             significant infection at the time of screening or randomization

          -  Subject is diagnosed with type 1 diabetes mellitus or diabetes mellitus with unclear
             etiology.

          -  Subject has a sitting systolic blood pressure (SBP) <90 or >160 mmHg and/or a
             diastolic blood pressure (DBP) >90 mmHg at screening.
      